Proneuron Biotechnologies, Inc. (US Branch) And Cell Design Of Atlanta To Establish A New Cell Processing Facility In Atlanta To Support The Current Phase II Trial Of ProCord For Complete Spinal Cord Injury
10/19/2005 5:11:37 PM
Proneuron Biotechnologies, Inc and Cell Design, L.L.C. announced today that the two companies have entered into an agreement to establish a new human cell processing facility in Atlanta to support the current Phase II study of Proneuron's Procord, autologous incubated macrophages for complete spinal cord injury. Cell Design, a subsidiary of Cell Dynamics, LLC, will provide the required cell processing facility for the manufacturing of ProCord in the southeast region of the U.S. for this international, multi-center, randomized-controlled clinical trial. The agreement with Cell Design will support Proneuron's collaboration with the Shepherd Center in Atlanta, which is anticipated to begin enrollment in 2004 and is already taking an active role in the study. Upon receipt of the requisite approval of the United States Food and Drug Administration, the facility will also provide for the commercial manufacturing of ProCord.
comments powered by